Halofuginone prevents extracellular matrix deposition in diabetic nephropathy

Biochemical and Biophysical Research Communications

Volumn 379, Issue 2, 2009, Pages 411-416

  Sato, Seiya ^a   Kawamura, Harukiyo ^a   Takemoto, Minoru ^a   Maezawa, Yoshiro ^a   Fujimoto, Masaki ^a   Shimoyama, Tatsushi ^a   Koshizaka, Masaya ^a   Tsurutani, Yuya ^a   Watanabe, Aki ^a   Ueda, Shiro ^b   Halevi, Karin ^c   Saito, Yasushi ^a   Yokote, Koutaro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c Collgard Biopharmaceuticals ^*  (Israel)

Author keywords

Diabetic nephropathy; Fibronectin; Halofuginone; Mesangial cell; Oxidative stress; TGF ; TGF type 2 receptor; Type I collagen

Indexed keywords

8 HYDROXYGUANINE; ALBUMIN; COLLAGEN TYPE 1; CREATININE; FEBRIFUGINE; FIBRONECTIN; GLUCOSE; HALOFUGINONE; HYDROETHIDINE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; EXTRACELLULAR MATRIX; FLUORESCENCE; GENE OVEREXPRESSION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; IN VIVO STUDY; MALE; MESANGIUM CELL; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; COLLAGEN TYPE I; DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; FIBRONECTINS; MESANGIAL CELLS; MICE; MICE, INBRED STRAINS; OXIDATIVE STRESS; PIPERIDINES; QUINAZOLINONES; RATS; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

MUS;

EID: 58149482604     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.088     Document Type: Article

References (24)

1. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am. J. Kidney Dis. 22 (1993) 736-744
2. Sharma K., and Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-β1 gene expression in diabetic BB rat and NOD mouse. Am. J. Physiol. 267 (1994) F1094-F1101
3. Border W.A., and Noble N.A. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Kidney Int. 54 (1998) 1390-1391
4. Davies M., Martin J., Thomas G.J., and Lovett D.H. Proteinases and glomerular matrix turnover. Kidney Int. 41 (1992) 671-678
5. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A., and Sharma K. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97 (2000) 8015-8020
6. Fujimoto M., Maezawa Y., Yokote K., Jo K., Kobayashi K., Kawamura H., Nishimura M., Roberts A.B., Saito Y., and Mori S. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem. Biophys. Res. Commun. 305 (2003) 1002-1007
7. Pines M., and Nagler A. Halofuginone: from veterinary use to human therapy. Drug Dev. Res. 50 (2000) 371-378
8. Gnainsky Y., Spira G., Paizi M., Bruck R., Nagler A., Abu-Amara S.N., Geiger B., Genina O., Monsonego-Ornan E., and Pines M. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes. J. Hepatol. 40 (2004) 269-277
9. McGaha T.L., Phelps R.G., Spiera H., and Bona C. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118 (2002) 461-470
10. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., Samuni A.M., Felici A., Reiss M., Yarkoni S., Sowers A., Mitchell J.B., Roberts A.B., and Russo A. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-β signaling by halofuginone. J. Biol. Chem. 279 (2004) 15167-15176
11. Nagler A., Katz A., Aingorn H., Miao H.Q., Condiotti R., Genina O., Pines M., and Vlodavsky I. Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone. Kidney Int. 52 (1997) 1561-1569
12. Benchetrit S., Yarkoni S., Rathaus M., Pines M., Rashid G., and Bernheim J. Halofuginone reduces the occurrence of renal fibrosis in 5/6 nephrectomized rats. Isr. Med. Assoc. J. 9 (2007) 30-34
13. Kreisberg J.I., Hoover R.L., and Karnovsky M.J. Isolation and characterization of rat glomerular epithelial cells in vitro. Kidney Int. 14 (1978) 21-30
14. Yokote K., Mori S., Hansen K., McGlade J., Pawson T., Heldin C.H., and Claesson-Welsh L. Direct interaction between Shc and the platelet-derived growth factor beta-receptor. J. Biol. Chem. 269 (1994) 15337-15343
15. Wrana J.L., Attisano L., Carcamo J., Zentella A., Doody J., Laiho M., Wang X.F., and Massague J. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71 (1992) 1003-1014
16. Yulia G., Gadi S., Melia P., Raffael B., Arnon N., Olga G., Rebbeca T., Halevy O., and Pines M. Involvement of the tyrosine phosphatase early gene of liver regeneration (PRL-1) in cell cycle and in liver regeneration and fibrosis effect of halofuginone. Cell Tissue Res. 324 (2006) 385-394
17. Baoheng D., Chenzhong F., Craig Kent K., Harry B., Andrew Schulick Jr. H., Karl K., Tucker C., and McC Timothy A. Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-β Type II receptor. J. Biol. Chem. 275 (2000) 39039-39047
18. Yee K.O., Connolly C.M., Pines M., and Lawler J. Halofuginone inhibits tumor growth in the polyoma middle T antigen mouse via a thrombospondin-1 independent mechanism. Cancer Biol. Ther. 5 (2006) 218-224
19. Arbell D., Udassin R., Koplewitz B.Z., Ohana M., Genina O., Pines M., and Nagler A. Prevention of esophageal strictures in a caustic burn model using halofuginone, an inhibitor of collagen type I synthesis. Laryngoscope 115 (2005) 1632-1635
20. Sun F., Iwagnchi K., Shudo R., Naqaki Y., Tanaka K., and Ikeda K. Change in tissue concentration of lipid hydroperoxides, vitamin C and vitamin E in rats with streptozotocin-induced diabetes. Clin. Sci. 96 (1999) 185-190
21. Adem K., Melih P., Yusuf E., Sinan C., Murat G., Fadil A., Hafize U., and Haydar D. The effect of halofuginone, a specific inhibitor of collagen type 1 synthesis, in the prevention of pancreatic fibrosis in an experimental model of severe hyperstimulation and obstruction pancreatitis. J. Surg. Res. 148 (2008) 7-12
22. Scivittaro V., Ganz M.B., and Weiss M.F. AGEs induce oxidative stress and activate protein kinase C-beta (II) in neonatal mesangial cells. Am. J. Physiol. Renal Physiol. 278 (2000) F676-F683
23. Leiba M., Cahalon L., Shimoni A., Lider O., Zanin-Zhorov A., Hecht I., Sela U., Vlodavsky I., and Nagler A. Halofuginone inhibits NF-κB and p38 MAPK in activated T cells. J. Leukoc. Bio. 80 (2006) 399-406
24. Sharma K., Jin Y., Guo J., and Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45 (1996) 522-530